The **Oncotype DX GPS Test** is for newly diagnosed prostate cancer patients with low-risk disease that helps identify the best management choice for their individual diagnosis.

The Oncotype DX GPS test analyzes the tumor, measuring the expression of certain genes in prostate cancer cells to determine how aggressive the cancer may be.

The test helps determine treatment options based on the aggressiveness of the cancer (i.e. how likely it is to grow and spread) — whether it can be monitored with active surveillance or if it should be treated immediately with surgery and/or radiation.

The Genomic Prostate Score (GPS) results range from 0-100 and help patients and their doctors better understand the biology of their prostate cancer to inform their treatment decision. The lower the GPS result, the lower the risk for an aggressive cancer.

For more information, visit [www.OncotypeIQ.com](http://www.OncotypeIQ.com).